A synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a naturally occurring actin-binding protein. Preclinical research describes improved cell migration, new blood-vessel formation and faster resolution of soft-tissue injury.
Actin regulation supports the cell migration that drives repair of muscle, tendon and ligament tissue.
New capillary formation improves circulation into poorly vascularized tissue such as tendon.
Injury models report reduced adhesion and scar formation, which is what usually limits mobility after a strain.
Downregulation of inflammatory mediators without the tissue-quality cost of repeated corticosteroid injections.
Unlike site-injected therapies, TB-500 distributes systemically, which matters when several areas are irritated at once.
Frequently paired with BPC-157: complementary mechanisms across angiogenesis and cell migration.
Thymosin Beta-4 is the primary actin-sequestering protein in most human cells. TB-500 reproduces its active binding domain, influencing how cells build and dismantle the cytoskeleton they need to move into an injury site.
Sequesters G-actin monomers, regulating the polymerization cells need to migrate.
Endothelial cells, keratinocytes and stem cells move into the injured region more readily.
New vessel formation restores oxygen and nutrient supply to healing tissue.
Reduced fibrotic adhesion supports better tissue quality rather than dense scar.
Most TB-500 data is preclinical or from early Thymosin Beta-4 trials in wound and corneal healing. Mechanistically it is well described, but large randomized trials in musculoskeletal injury have not been completed. We prescribe it off-label with that stated plainly.
TB-500 is widely sold as an unregulated research chemical. Ours is compounded by a licensed U.S. pharmacy under prescription with certificates of analysis for purity and potency.
Protocols typically run a higher twice-weekly loading phase for four to six weeks, then a lower maintenance dose, then a washout before reassessment.
TB-500 is prohibited under WADA's S2 category. Competitive athletes subject to testing should not use it.
Review of Thymosin Beta-4 in tissue protection, repair and regeneration across multiple organ models.
Annals of the New York Academy of Sciences
Thymosin Beta-4 accelerated keratinocyte migration and wound closure in animal models.
The FASEB Journal
Clinical work in corneal wound healing supporting anti-inflammatory and regenerative activity.
Expert Opinion on Biological Therapy
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–4 | 2.5 mg twice weekly | Loading phase. |
| Weeks 5–8 | 2.5 mg once weekly | Maintenance. |
| Weeks 9+ | 2.5 mg every 2 weeks | Optional extended maintenance. |
| Washout | — | 4 weeks off before repeating a cycle. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| TB-500 | Actin-binding, cell migration | — | 2x weekly |
| BPC-157 | Cytoprotective / angiogenic | — | Daily |
| CJC-1295 / Ipamorelin | GH secretagogue | — | Nightly |
No. It is prescribed off-label and compounded by a licensed U.S. pharmacy. Human trial data in musculoskeletal injury is limited, and your physician will review that with you.
BPC-157 is dosed daily and often near the affected area; TB-500 is dosed twice weekly and acts systemically. Many patients run them together.
Subcutaneously, typically in the abdomen. Because it distributes systemically, it does not need to be injected near the injury.
Most protocols run six to eight weeks, then a four-week washout and reassessment with your physician.
The clinical gold standard for appetite regulation.
View protocolDual incretin action for the deepest documented weight reduction.
View protocolA gastric peptide studied for systemic tissue repair.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolA mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolAn on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolThe original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.